



28 August 2026

Medicine Supply Alert Notice

Beclometasone dipropionate (Clenil Modulite®) 50micrograms/dose and 250 micrograms/dose inhalers

Priority: Level 2*

Valid until: noted products are being discontinued

Issue

1. Beclometasone dipropionate (Clenil Modulite®) 50micrograms/dose and 250micrograms/dose inhalers will be discontinued at the end of November 2026.
2. Beclometasone dipropionate (Soprobec®) 50micrograms/dose and 250micrograms/dose inhalers remain available and can support increased demand.
3. Beclometasone dipropionate (Clenil Modulite®) 100micrograms/dose inhaler remains available and can support an increased demand for patients where appropriate (see below).
4. Beclometasone dipropionate CFC-free pressurised metered dose inhalers (pMDIs), Qvar® and Kelhale®, remain available for patients where appropriate (see below).

Advice and Actions

5. Prescribers should:
 - not initiate any new patients on Clenil Modulite® 50micrograms/dose or 250micrograms/dose inhalers;
 - review patients currently prescribed Clenil Modulite® 50micrograms/dose and 250microgram/dose inhalers to determine whether this remains the most appropriate therapy or if their treatment regimen should be amended in line with current [BTS/NICE/SIGN guidance](#) recommending combination inhalers that deliver AIR and MART therapy;
 - consider prescribing Clenil Modulite® 100micrograms/dose inhalers for patients using 2 puffs of Clenil Modulite® 50micrograms/dose to deliver 100micrograms per dose, ensuring the patient is counselled on this change;
 - consider prescribing Soprobec® 50micrograms/dose or 250micrograms/dose inhaler, ensuring that the patient:
 - can use an inhaler **without a dose counter**;
 - is counselled that the although the inhaler differs in colour, it delivers the same drug, and dosing remains the same;
 - is provided with training to ensure correct use of the inhaler; and
 - is given advice on how to keep track of doses used to ensure adherence to treatment as well as timely requests for repeat prescriptions (see Additional Information below).

- consider prescribing on a case-by-case basis, Qvar® inhalers for patients aged 5 and above or Kelhale® inhalers for adults who can benefit from a dose counter (see NOTE below).
6. If the above options are not considered appropriate, refer to local/national guidance for selection of another management option or seek Advice and Guidance from specialists.

Additional Information

Clinical Information

7. Clenil Modulite® and Soprobec® are pressurised metered dose inhalers (pMDI) delivering the same dose of beclometasone. They are licensed for the prophylactic management of asthma. The Volumatic™ spacer device is compatible with both inhalers.
8. Unlike Clenil Modulite®, Soprobec® inhalers lack a dose counter. [BTS/NICE/SIGN guidance](#) on asthma recommends that choice of inhaler should be based on an assessment of correct technique, patient preference, lowest environmental impact among suitable devices, and the presence of an integral dose counter. For inhalers without a dose counter, patients should be advised on how to calculate how many days the inhaler should last and mark on a calendar or set a reminder to alert them at least a week before it is due to run out. They should also document how many puffs are being used. There are mobile phone apps available to help keep track of inhaler usage.
9. [BTS/NICE/SIGN guidance](#) recommends that the initial management for newly diagnosed asthma in people aged 12 years and over should now be with either:
 - low-dose inhaled corticosteroid/formoterol combination to be taken as-needed (Anti-inflammatory reliever [AIR] therapy) or
 - low-dose maintenance and reliever (MART) therapy for patients with highly symptomatic asthma (e.g. regular nocturnal waking) or with a severe exacerbation, which can be stepped down to as-needed AIR therapy, if asthma is controlled.
10. **NOTE: The beclometasone dipropionate CFC-free pMDIs, Qvar® and Kelhale®, are not interchangeable with Clenil Modulite® as they contain extra-fine particles and are approximately twice as potent as Clenil Modulite®. All beclometasone dipropionate CFC-free pMDIs should be prescribed by brand name.**

Links to further information

- [BNF beclometasone dipropionate](#)
- [BTS/NICE/SIGN Joint Guideline on Asthma: diagnosis, monitoring and chronic asthma management](#)
- [Medicines for Children- Asthma article 5: Make sure you're not running on empty!](#)
- [Soprobec® inhaler SmPC](#)
- [Kelhale® inhalers SmPC](#)
- [Qvar® inhalers SmPC](#)

Specialist Pharmacy Service (SPS) website

11. The UK Department of Health and Social Care (DHSC) in conjunction with the Specialist Pharmacy Service (SPS) have launched an online Medicines Supply Tool, which provides up to

date information about medicine supply issues. To access the online Medicines Supply Tool you need to register with the [SPS website](#). Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.

12. Prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland are encouraged to register with the SPS website and use its Medicine Supply Tool to stay up to date concerning medicines supply disruptions. Please be aware that while medicines supply issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

Enquiries

13. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to PharmacyTeam@gov.scot (primary care) or NSS.NHSSMedicineShortages@nhs.scot (secondary care).